Find trials
Search tips

Homocysteine Metabolism and Endothelial Function in ADPKD

Overview

About this study

The purpose of this study is to assess homocysteine metabolism and endothelial function at early stages of ADPKD and how these influence microvascular function and renal disease severity and progression. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male and female subjects, 15 - 40 years of age.
  • Previous diagnosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (based on Ravine et al. criteria).
  • Class 1 A-E according to imaging classification
  • Estimated GFR > 70 mL/min/1.73 m^2 (CKD-EPI).
  • Ability to provide written, informed consent.

Exclusion Criteria:

  • Class 2 according to imaging classification.
  • Concomitant systemic disease affecting the kidney.
  • Diabetes mellitus.
  • Predicted urine protein excretion in > 1 g/24 hrs, and or Abnormal urinalysis.
  • Patients that are part on an interventional study or are taking tolvaptan.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Maria Irazabal Mira, M.D., Ph.D.

Open for enrollment

Contact information:

Maria Irazabal Mira M.D., Ph.D.

(507) 884-5628

IrazabalMira.Maria@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20520136

Mayo Clinic Footer